Hepatitis C in liver transplant patients

Gane EJ, Portmann BC, Naoumov NV, et al.: Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996, 334:815–820.

Berenguer M, Ferrell L, Watson J, et al.: HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000, 32:673–684.

Berenguer M, Prieto M, Rayon JM, et al.: Natural history of clinically compensated HCV-related graft cirrhosis after liver transplantation. Hepatology 2000, 32:852–858.

Forman LM, Lewis JD, Berlin JA, et al.: The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002, 122:889–896.

Kemmer N, Kaiser TE, Zacharias V, et al.: Revisiting posttransplant survival for hepatitis C virus recipients. Transplantation 2007, 84:932–933.

Cammà C, Di Bona D, Schepis F, et al.: Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004, 39:333–340.

Poynard T, McHutchison J, Manns M, et al.: Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002, 122:1303–1313.

Veldt BJ, Heathcote EJ, Wedemeyer H, et al.: Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007, 147:677–684.

Iacobellis A, Siciliano M, Perri F, et al.: Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007, 46:206–212.

Weksler BB: Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. Aliment Pharmacol Ther 2007, 26:13–19.

Di Bisceglie AM, Shiffman ML, Everson GT, et al.: Prolonged antiviral therapy with peginterferon to prevent complications of advanced liver disease associated with hepatitis C: results of the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial. Hepatology 2007, 46(Suppl 1):290A.

Everson GT, Trotter J, Forman L, et al.: Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005, 42:255–262.

Sherman M: Optimizing management strategies in special patient populations. Am J Gastroenterol 2006, 101(Suppl 1):S26–S31.

Lee LP, Dai CY, Chuang WL, et al.: Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patients. J Gastroenterol Hepatol 2007, 22:515–517.

Cheruvu S, Marks K, Talal AH: Understanding the pathogenesis and management of hepatitis B/HIV and hepatitis B/hepatitis C virus coinfection. Clin Liver Dis 2007, 11:917–943.

Merchante N, Jiménez-Saenz M, Pineda JA: Management of HCV-related end-stage liver disease in HIV-coinfected patients. AIDS Rev 2007, 9:131–139.

McGovern BH: Hepatitis C in the HIV-infected patient. J Acquir Immune Defic Syndr 2007, 45:S47–S45.

Bonacini M: Diagnosis and management of cirrhosis in coinfected patients. J Acquir Immune Defic Syndr 2007, 45:S38–S44.

Morra R, Munteanu M, Imbert-Bismut F, et al.: FibroMAX: towards a new universal biomarker of liver disease? Expert Rev Mol Diagn 2007, 7:481–489.

Halfon P, Bourliere M, Deydier R, et al.: Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol 2006, 101:547–555.

Huwart L, Sempoux C, Salameh N, et al.: Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index. Radiology 2007, 245:458–460.

Talwalkar JA, Kurtz DM, Schoenleber SJ, et al.: Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2007, 5:1214–1220.

Roche B, Samuel D: Risk factors for hepatitis C recurrence after liver transplantation. J Viral Hepat 2007, 14:89–96.

Cameron AM, Ghobrial RM, Hiatt JR, et al.: Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg 2006, 244:563–571.

Onaca NN, Levy MF, Netto GJ, et al.: Pretransplant MELD score as a predictor of outcome after liver transplantation for chronic hepatitis C. Am J Transplant 2003, 3:626–630.

Briceño J, Ciria R, Pleguezuelo M, et al.: Contribution of marginal donors to liver transplantation for hepatitis C virus infection. Transplant Proc 2007, 39:2297–2299.

Botha JF, Thompson E, Gilroy R, et al.: Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation. Liver Int 2007, 27:758–763.

Rayhill SC, Wu YM, Katz DA, et al.: Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C. Transplantation 2007, 84:331–339.

Belli LS, Burroughs AK, Burra P, et al.: Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl 2007, 13:733–740.

Gaglio PJ, Malireddy S, Levitt BS, et al.: Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl 2003, 9:1028–1035.

Terrault NA, Shiffman ML, Lok AS, et al.: A2ALL Study Group: Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 2007, 13:122–129.

Lee KW, Simpkins CE, Montgomery RA, et al.: Factors affecting graft survival after liver transplantation from donation after cardiac death donors. Transplantation 2006, 82:1683–1688.

Dezza MC, Berrevoet F, Sainz-Barriga M, et al.: The choice of recipient does not have a bearing on early outcome in liver transplant patients receiving grafts from non-heart-beating donors: a reappraisal? Transplant Proc 2007, 39:2675–2677.

Katz LH, Mor E, Brown M, et al.: Recurrent hepatitis C virus disease after liver transplantation and concurrent biliary tract complications: poor outcome. Clin Transplant 2006, 20:465–470.

Klintmalm GB, Washburn WK, Rudich SM, et al.: Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007, 13:1521–1531.

Vivarelli M, Burra P, Barba GL, et al.: Influence of steroids on HCV recurrence after liver transplantation: a prospective study. J Hepatol 2007, 47:793–798.

Berenguer M, Royuela A, Zamora J: Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007, 13:21–29.

Guitard J, Sandres-Sauné K, Kamar N: Hepatitis C virus viral load after conversion from tacrolimus to cyclosporine in liver transplant patients. Transplant Proc 2007, 39:2603–2605.

Bahra M, Neumann UP, Jacob D, et al.: Repeated steroid pulse therapies in HCV-positive liver recipients. Transplant Proc 2005, 37:1700–1702.

Wiesner RH, Shorr JS, Steffen BJ, et al.: Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 2005, 11:750–759.

Kwo PY, Saxena R, Cummings OW, et al.: Intravenous interferon during the anhepatic phase of liver retransplantation and prevention of recurrence of cholestatic hepatitis C virus. Liver Transpl 2007, 13:1710–1713.

Arjal RR, Burton JR Jr, Villamil F, et al.: Review article: the treatment of hepatitis C virus recurrence after liver transplantation. Aliment Pharmacol Ther 2007, 26:127–140.

Wiesner RH, Sorrell M, Villamil F, et al.: Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003, 9:S1–S9.

Saab S, Oh MK, Ibrahim AB, et al.: Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. Liver Transpl 2007, 13:1032–1038.

Schecter JM, Mears JG, Alobeid B, et al.: Anti-erythropoietin antibody-mediated pure red cell alpasia in a living donor liver transplant recipient treated for hepatitis C virus. Liver Transpl 2007, 13:1589–1592.

Picciotto FP, Tritto G, Lanza AG, et al.: Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007, 46:459–465.

Kornberg A, Küpper B, Tannapfel A, et al.: Antiviral maintenance treatment with interferon and ribavirin for recurrent hepatitis C after liver transplantation: pilot study. J Gastroenterol Hepatol 2007, 22:2135–2142.

McCashland T, Watt K, Lyden E, et al.: Retransplantation for heaptitis C: results of a U.S. multicenter retransplant study. Liver Transpl 2007, 13:1246–1253.